

Curriculum vitae

Dr. med. Cornelia Liedtke

Tel.: 0049-251-7984892

email: cornelia.liedtke@ukmuenster.de



Personal Details:

Name	Cornelia Liedtke, MD
Address (private)	Elsässer Straße 43 48151 Muenster, Germany
Address (professional)	University Hospital Münster Department of Gynecology and Obstetrics, Albert-Schweitzer Straße 33 48149 Münster, Germany
Date of Birth	December 26, 1979
Place of Birth	Rheda-Wiedenbrück, Germany

Education

Primary Education

1986-1990	Elementary School, Langenberg
1990-1999	Marienschule Lipperbruch (Private Gymnasium for Boys and Girls)
1999	Graduation

Higher Education

- 10/1999 – 2005 Medical studies at the *Westfälische Wilhelms-Universität (WWU)*, Münster, Germany
- 2001 Pre-clinical examinations
- 2002 Primary State Examination
- 2/2004-4/2004 Medical Practical Training at *Christie Hospital*, Manchester, UK, Medical/Clinical Oncology (8 weeks)
- 2004 Secondary State Examination
- 10/2004-02/2005 Medical Practical Training at *Tulane University*, New Orleans, LA, USA, Internal Medicine (Allergy/ Immunology/ Rheumatology, Hematology/ Oncology, Infectious Diseases) (16 weeks)
- 10/24/2005 Tertiary State Examination
- 12/2005-10/2006 Assistant doctor at the *Universitätsklinikum Münster*, Münster, Germany, Department of Gynecology and Obstetrics
- 26/01/2006 completion of MD thesis, doctorate
- 11/2006-04/2008 postdoc at *The University of Texas M. D. Anderson Cancer Center (UT MDACC)*, Houston, TX, USA, Breast Medical Oncology
- 05/2008 - today Assistant doctor at the *Universitätsklinikum Münster*, Münster, Germany, Department of Gynecology and Obstetrics

MD-thesis

C. Liedtke: "Frequency of CA-SSR-I-amplifications of the EGFR gene in malignant and benign tumors of the female breast correlated with EGFR-whole-gene-amplifications and EGFR-overexpression." *Westfälische Wilhelms-Universität*, Münster, Germany, January 2006

Grants/ scholarships

- 11/2006-10/2007 dfg-research scholarship at *The University of Texas M. D. Anderson Cancer Center (UT MDACC)*, Breast Medical Oncology
- 09/2007 dfg-travel scholarship for the *ASCO Breast Cancer Symposium*, San Francisco, September 2007

Awards:

- Susan G. Komen for the Cure-AACR Scholar-in-Training Award 2008, 31st Annual CTRC-AACR San Antonio Breast Cancer Symposium
- Christan-Lauritzen-Preis der Deutschen-Menopause-Gesellschaft 2009

Memberships:

- American Society of Clinical Oncology (ASCO), since 2007
- American Association of Cancer Research (AACR), 2009-2010
- TraFo Subboard, German Breast Group (GBG), since 2009
- SENTINA Study, Protocol Board, since 2009
- Arbeitsgemeinschaft Gynäkologische Onkologie (AGO), since 2008

Original Publications (first author)

Liedtke C, Kersting C, Bürger H, Kiesel L, Wülfing P. Caveolin-1 expression in benign and malignant lesions of the breast. *World J Surg Oncol*. 2007 Oct 3;5:110

Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Puztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. *J Clin Oncol*. 2008 Mar 10;26(8):1275-81

Liedtke C, Cardone L, Tordai A, Yan K, Gomez HL, Barajas Figureoa LJ, Hubbard RE, Valero V, Souchon EA, Symmans WF, Hortobagyi GN, Bardelli A, Puztai L. PIK3CA activating mutations and chemotherapy sensitivity in stage II-III breast cancer. *Breast Cancer Res*. 2008 Mar 27;10(2):R27

Liedtke C, Hatzis C, Symmans WF, Desmedt C, Haibe-Kains B, Valero V, Kuerer H, Hortobagyi GN, Piccart-Gebhart M, Sotiriou C, Puztai L. The Genomic Grade Index (GGI) Is Associated with Response to Chemotherapy in patients with Breast Cancer. *J Clin Oncol*. 2009 27(19):3185-91

Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstamm F, Woodward W, Theriault R, Kiesel L, Hortobagyi GN, Puztai L, Gonzalez-Angulo A. Prognostic impact of discordance between triple receptor measurements in primary and recurrent breast cancer. *Ann Onc* 2009 (in press)

Liedtke C, Wang J, Tordai A, Symmans WF, Hortobagyi GN, Kiesel L, Hess KR, Baggerly KA, Coombes KR, Puztai L. Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. *Breast Cancer Res Treat* 2009 (in press)

Original Publications (coauthor)

Kersting C, Tidow N, Schmidt H, **Liedtke C**, Neumann J, Boecker W, van Diest PJ, Brandt B, Buerger H. Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma. *Lab Invest.* 2004;84(5):582-7.

Korsching E, Packeisen J, **Liedtke C**, Hungermann D, Wülfing P, van Diest PJ, Brandt B, Boecker W, Buerger H. The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? *J Pathol.* 2005;206(4):451-7.

Kersting C, Kuijper A, Schmidt H, Packeisen J, **Liedtke C**, Tidow N, Gustmann C, Hinrichs B, Wülfing P, Tio J, Boecker W, van Diest P, Brandt B, Buerger H. Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression. *Lab Invest.* 2006;86(1):54-61.

Andre F, Mazouni C, **Liedtke C**, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. *Breast Cancer Res Treat.* 2008; 108(2):183-90

Tordai A, Wang J, Andre F, **Liedtke C**, Yan K, Sotiriou C, Hortobagyi GN, Symmans WF, Pusztai L. Evaluation of biological pathways involved in chemotherapy response in breast cancer. *Breast Cancer Res.* 2008;10(2):R37

Zoubir M, Mathieu MC, Mazouni C, **Liedtke C**, Corley L, Geha S, Bouaziz J, Spielmann M, Drusche F, Symmans WF, Delaloge S, Andre F. Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy. *Ann Oncol.* 2008;19(8):1402-6

Helms MW, Kemming D, Pospisil H, Vogt U, Buerger H, Korsching E, **Liedtke C**, Schlotter CM, Wang A, Chan SY and Brandt BH. Squalene epoxidase, located on chromosome 8q24.1, is upregulated in 8q+ breast cancer and indicates poor clinical outcome in stage I and II disease. *Br J Cancer.* 2008;99(5):774-80

Andre F, Job B, Dessen P, Tordai A, Michiels S, **Liedtke C**, Richon C, Yan K, Wang B, Vassal G, Delaloge S, Hortobagyi GN, Symmans WF, Lazar V, Pusztai L. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. *Clin Cancer Res.* 2009;15(2):441-51

Rody A, Holtrich U, Pusztai L, **Liedtke C**, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. *Breast Cancer Res.* 2009;11(2):R15.

Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, **Liedtke C**, Barnett CM, Limin Hsu, Hung MC, Hortobagyi GN, and Gonzalez-Angulo AM. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. *J Clin Oncol.* 2009 27(20):3297-302

Reviews

Liedtke C, Kiesel L (2006) Dysfunktional uterine bleeding. *Gyn Endokrinologie* 4 (4): 235-248

Liedtke C, André F (2007) Gene-Expression Biomarkers as Predictors of Recurrence and Treatment-Related Outcomes in Breast Cancer. *Breast Diseases: A Year Book® Quarterly* (18)2:133-135

Pusztai L, **Liedtke C**, Tordai A (2007) Gene expression profiling to select patients for chemotherapy. *ASCO Educational Book* 1092-9118:64-66, 2007.

Liedtke C., Gonzalez-Angulo AM. Commentary on article by Rakha EA, et al entitled "Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes". *Eur J Cancer.* 2008 44(1):73-83. *Breast Diseases: A Year Book® Quarterly* 2008;19:277-2

Liedtke C, Kiesel L. Postmenopausale Hormontherapie und Mammakarzinomrisiko - Ein Update. *Gynäkologe.* 2008;41:865–873

Liedtke C, Kiesel L. Bedeutung von Biomarkern in der Klassifizierung und Therapie des Mammakarzinoms. *Senologie - Zeitschrift für Mammadiagnostik und -therapie* 2008;5:257-263

Gluz O, **Liedtke C**, Nitz U, Harbeck N. Molekulare Mechanismen der Chemoresistenz und Möglichkeiten der Überwindung. Geburtshilfe und Frauenheilkunde 2009 (in press)

Liedtke C, Kiesel L. Hormonsubstitution bei Patientinnen mit Mammakarzinom. GynSpectrum 2009; 01: 14-15

Liedtke C, Kiesel L. Das tripelnegative / basale Mammakarzinom. GebFra 2009 (in press)

Tordai A, **Liedtke C**, Pusztai L.vMetastatic gene signatures and emerging novel prognostic tests in the management of early stage breast cancer. Clin Exp Metastasis. 2009 Apr 18.

Liedtke C, Kiesel L. Die Bedeutung von Mikroarrays für das Mammakarzinom, Gynäkologische Endokrinologie 2009; 02 DOI 10.1007/s10304-009-0303-z

Gluz O, **Liedtke C**, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer—current status and future directions. Ann Onc (in press)

Selected Abstracts:

C. Liedtke, J. Packeisen, C. Kersting, B. Brandt, L. Kiesel, H. Buerger. In vitro chemosensitivity testing in invasive breast cancer – increased sensitivity of the basal subtype is not independent of the tumour proliferation rate. AACR - Molecular Diagnostics in Cancer Therapeutic Development, Chicago, USA, September 12-15, 2006 (B15) **Poster presentation**

C. Liedtke, H. Bürger, C. Kersting, M. Helms, B. Brandt, L. Kiesel. Expression der HER2-assoziierten Proteine Tob, TGFbeta und P4HB beim mammären Morbus Paget. German Society of Gynecology and Obstetrics, Berlin, Germany, September 19–22, 2006; Geburtsh Frauenheilk 2006; 67 **Poster presentation**

C. Liedtke, H. Bürger, C. Kersting, M. Helms, B. Brandt, L. Kiesel. Expression of the HER2-associated proteins Tob-1, TGFbeta und P4HB in mammary Paget's disease. 29th Annual San Antonio Breast Cancer Symposium – December 14–17, 2006. Breast Cancer Research and Treatment. VOL. 100, Supplement 1, S 253. **Poster presentation**

- Tordai A, Wang B, André F, **Liedtke C**, Symmans WF, Esteva FJ, **Poster presentation**
Pusztai L. Screening for expression of novel marker proteins for triple negative breast cancer in breast cancer cell lines. [abstract]. In: American Association for Cancer Research Annual Meeting: Proceedings; 2007 Apr 14-18; Los Angeles, CA. Philadelphia (PA): AACR; 2007. Abstract nr 1978
- C. Liedtke**, C. Mazouni, KR. Hess, A. Tordai, F. André, WF. **Poster discussion**
Symmans, AM. Gonzalez-Angulo, M. Green, GN. Hortobagyi, L. Pusztai Differential response to primary chemotherapy and long-term outcome in patients with triple-negative breast cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 10519
- C. Liedtke**, A. Tordai, J. Wang, F. André, K. Yan, C. Sotiriou, G. N. **Poster presentation**
Hortobagyi, W. F. Symmans, L. Pusztai. Gene set enrichment analysis to evaluate biological pathways involved in chemotherapy response in breast cancer. The Breast Cancer Symposium, September 2007, abstract #99
- Liedtke C**, Yan K, Wang J, Wang B, Zhang J, Tordai A, Symmans **Poster presentation**
WF, Mejia JA, Valero V, Hortobagyi GN, Pusztai L. Molecular characterization of triple-negative breast cancers using gene expression profiling. [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008 Apr 12-16; San Diego, CA. Philadelphia (PA): AACR; 2008. Abstract nr 5491
- Zoubir M, Mathieu M, **Liedtke C**, Bidard F, Delaloge S, Corley L, **Poster presentation**
Spielmann M, Pusztai L, André F, Symmans WF. Predictive biomarkers for preoperative endocrine therapy of stage II-III breast cancer by tissue microarrays. J Clin Oncol 26: 2008 (May 20 suppl; abstr 560)
- Hubbard R, Peintinger F, **Liedtke C**, Hatzis C, Kuerer HM, Valero **Poster presentation**
V, Buzdar AU, Hortobagyi GN, Pusztai L, Symmans WF. Residual cancer burden after neoadjuvant taxane-anthracycline chemotherapy is independently prognostic in every phenotypic

subset of breast cancer. J Clin Oncol 26: 2008 (May 20 suppl; abstr 544)

Dean-Colomb W, Yan K, **Liedtke C**, Symmans W, Holmes FA, O'Shaughnessy J, Asmar L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. Transcriptional profiles of triple receptor-negative breast cancer: are Caucasian, Hispanic and African-American different? J Clin Oncol 26: 2008 (May 20 suppl; abstr 22014) **Publication only**

Broglio K, Moulder S, Hsu L, Kau S, Pusztai L, Symmans WF, Hortobagyi G, Gonzalez-Angulo A, **Liedtke C (presenter)**. Prognostic impact of discordance/ concordance of triple-receptor expression between primary tumor and metastasis in patients with metastatic breast cancer. J Clin Oncol 26: 2008 (May 20 suppl; abstr 1001) **Oral presentation (pres: Liedtke)**

Symmans WF, Hatzis C, **Liedtke C**, Desmedt C, Valero V, Kuerer H, Hortobagyi GN, Piccart-Gebhart M, Pusztai L, Sotiriou C. Genomic Grade Index (GGI) predicts pathologic response to preoperative chemotherapy in breast cancer. J Clin Oncol 26: 2008 (May 20 suppl; abstr 541) **Poster presentation**

Liedtke C, Cardone A, Tordai A, Gomez HL, Barajas LJ, Valero V, Symmans WF, Hortobagyi GN, Bardelli A, Pusztai L. PIK3CA activating mutations and chemotherapy sensitivity in stage II-III breast cancer. J Clin Oncol 26: 2008 (May 20 suppl; abstr 11500) **Poster presentation**

Liedtke C, Yan K, Wu Y, Hortobagyi GN, Symmans WF, Valero V, Goette M, Kiesel L, Pusztai L. Targeting of breast cancer cells with non-oncology drugs – possible novel therapeutic option for triple-negative breast cancer. Cancer Res 2008; 69 (Suppl): 193s **Poster presentation**

Ruckert C, Dugas M, Kiesel L, **Liedtke C**. Differentielle Genexpressionsanalyse zwischen früh- und spätrezidivierten Mammakarzinomen. 29. Jahrestagung der Deutschen Gesellschaft für Senologie, Düsseldorf, 11. – 13. Juni 2009, P034 **Poster presentation**

Book Chapters:

C. Liedtke, Puztai L. Pharmacogenetics of breast cancer: Towards the individualization of therapy. In: Gene expression profiling as an emerging diagnostic tool to personalize chemotherapy selection for early stage breast cancer. 6. Ed(s) Leyland-Jones B. Informa Healthcare: London, 77-96, 2008.

C. Liedtke, L. Puztai, WF. Symmans. Molecular Pathology and transcriptional profiling in early drug development. In: Molecular Pathology in Drug Discovery and Development. Ed. Suso Platero. John Wiley & Sons, Inc, Hoboken, NJ (anticipated for 2009)

November, 2009